Literature DB >> 24604016

[Botulinum neurotoxin type A in neurogenic detrusor overactivity: consensus paper of the Working Group Neuro-Urology of the DMGP].

R Böthig1, A Kaufmann, J Bremer, J Pannek, B Domurath.   

Abstract

The use of botulinum neurotoxin (BoNT-A) for suppression of neurogenic detrusor overactivity was first reported in 2000. Since that time, this method has gained widespread use. A number of recommendations and consensus statements have already been published. The current practice-oriented consensus paper takes into account recent developments and the over 10-year experience of most members of the Working Group Neuro-Urology of the German-speaking Medical Society for Paraplegia (DMGP) with a focus on the use of BoNT-A in paraplegic patients and in patients with multiple sclerosis.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24604016     DOI： 10.1007/s00120-013-3419-7

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  5 in total

Review 1.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

2.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

3.  Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Authors:  Francisco Cruz; Sender Herschorn; Philip Aliotta; Mitchell Brin; Catherine Thompson; Wayne Lam; Grace Daniell; John Heesakkers; Cornelia Haag-Molkenteller
Journal:  Eur Urol       Date:  2011-07-13       Impact factor: 20.096

Review 4.  Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

Authors:  Apostolos Apostolidis; Prokar Dasgupta; Pierre Denys; Sohier Elneil; Clare J Fowler; Antonella Giannantoni; Gilles Karsenty; Heinrich Schulte-Baukloh; Brigitte Schurch; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

Review 5.  A UK consensus on the management of the bladder in multiple sclerosis.

Authors:  C J Fowler; J N Panicker; M Drake; C Harris; S C W Harrison; M Kirby; M Lucas; N Macleod; J Mangnall; A North; B Porter; S Reid; N Russell; K Watkiss; M Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154
  5 in total
  1 in total

1.  [Neuro-urological diagnosis and therapy of lower urinary tract dysfunction in patients with spinal cord injury : S2k Guideline of the German-Speaking Medical Society of Paraplegia (DMGP), AWMF register no. 179/001].

Authors:  R Böthig; B Domurath; A Kaufmann; J Bremer; W Vance; I Kurze
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.